Claims for Patent: 5,147,868

Summary for Patent: 5,147,868

Title:	Thienamycin renal peptidase inhibitors
Abstract:	Novel chemical compounds are provided which selectively inhibit the metabolism of dipeptidase (E.C.3.4.13.11) and therefore are useful in combination with antibacterial products. These chemical compounds are z-2-acylamino-3-monosubstituted propenoates.
Inventor(s):	Graham; Donald W. (Mountainside, NJ), Rogers; Edward F. (Middletown, NJ), Kahan; Frederick M. (Scotch Plains, NJ)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Application Number:	07/839,725
Patent Claims:	1. A compound of the formula ##STR80## R1 is hydrogen or a pharmaceutically acceptable cation; R2 is X or Y wherein X is unsubstituted or substituted branched or linear alkyl of three to ten carbon atoms wherein a non-terminal methylene can be replaced by oxygen, sulfur or SO2, where said substituents are selected from the group consisting of halogen or cycloalkyl of three to six carbon atoms, with the proviso that, when said alkyl is substituted by said cycloalkyl, X is not more than ten total carbon atoms, with the further proviso that not more than six hydrogens of said alkyl can be substituted by said halogen, and with the further proviso that the carbon adjacent to the carbonyl cannot be tertiary; Y is cycloalkyl of three to six carbon atoms, unsubstituted or substituted with one or two substituents where said substituents are selected from the group consisting of halogen or alkyl of one to four carbon atoms, with the proviso that, when said cycloalkyl is substituted by said alkyl, Y is not more than ten total carbon atoms; R.sup.3 is unsubstituted or substituted two to fifteen carbon alkyl wherein said substituent is halogen, and wherein a non-terminal methylene can be replaced by oxygen, sulfur or SO.sub.2 and wherein the terminal carbon of said alkyl can be substituted by a moiety selected from the group consisting of amino, ureido, amidino, guanidino, one to four carbon alkylamino, dialkylamino of one to four carbons per alkyl substituent, trialkylammonium, quaternary hydroxyalkyldialkylammonium, acylamino, phosphonylalkylamino, hydroxyalkylamino, formamidino, alkylamidino, N,N-dialkylguanidino, hydroxyl, alkylcarbonyloxy, alkoxycarbonyl, carbamoyl, N,N dialkylcarbamoyl, thiol, acylthio, carboxy, phosphono, cyano, L-2-amino-2-carboxyethylthio or N-methyl-N-carboxymethylamino, with the proviso that no more than six hydrogens of said one to fifteen carbon alkyl can be substituted by halogen, with the further proviso that when R.sup.3 is straight chain lower alkyl of one to four carbon atoms, R.sup.2 cannot be straight chain lower alkyl of one to four carbon atoms, with the further proviso that the compound of the structural formula given above has the Z stereoconfiguration. 2. The compound of claim 1 in which R.sup.2 is 2,2-dimethylcyclopropyl. 3. The compound of claim 1 in which R.sup.2 is 2,2-dichlorocyclopropyl. 4. The compound of claim 1 which is Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-[1-(phosphono)-ethylamino]-2-o ctenoic acid. 5. The compound of claim 1 which is Z-8-[(carboxymethyl)methylamino]-2-(2,2-dimethylcyclo-propanecarboxamido)- 2-octenoic acid. 6. The compound of claim 1 which is Z-8-[(2-amino-2-oxoethyl)thio]-2-(2,2-dimethylcyclopropane-carboxamido)-2- octenoic acid. 7. The compound of claim 1 which is Z-8-cyano-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid. 8. The compound of claim 1 which is Z-8-acetamido-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid. 9. A compound of the formula ##STR81## R.sup.2 is 2,2-dimethylcyclopropyl or 2,2-dichlorocyclopropyl; R.sup.1 is hydrogen, loweralkyl of 1-6 carbon atoms, dialkylaminoalkyl, or a pharmaceutically acceptable cation; R.sup.3 is a hydrocarbon chain of 3-7 carbon atoms unsubstituted or substituted with a terminal substituent taken from the group consisting of trimethylammonium, amidino, guanidino, 2-amino-2-carboxyethylthio and ureido. 10. The compound of claim 9 which is Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid. 11. The compound of claim 9 in which is the 2-dimethylaminoethyl ester of Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid. 12. The compound of claim 9 which is Z-2-(2,2-dichlorocyclopropanecarboxamido)-2-octenoic acid. 13. The compound of claim 9 which is Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-trimethylammonium-2-octenoic acid inner salt. 14. The compound of claim 9 which is Z-2-(2,2-dichlorocyclopropanecarboxamido)-8-trimethylammonium-2-octenoic acid inner salt. 15. The compound of claim 9 which is Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-guanidino-2-octenoic acid. 16. The compound of claim 9 which is Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-amidino-2-octenoic acid. 17. The compound of claim 9 which is Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-ureido-2-octenoic acid. 18. The compound of claim 9 which is 6-(L-2-amino-2-carboxyethylthio)-2-(2,2,-dimethylcyclopropanecarboxamido)- 2-hexenoic acid. 19. The compound of claim 9 which is 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamido)-2 -heptenoic acid. 20. The compound of claim 19 in the sodium, potassium, calcium or magnesium salt form. 21. The compound of claim 1 in which R.sup.2 is 2,2-dihalocyclopropyl. 22. The compound as claimed in claim 1, in which R.sup.2 is cycloalkyl of three to six carbon atoms substituted by two alkyl substituents of one to three carbon atoms each, witho the proviso that R.sup.2 cannot contain more than ten carbon atoms. 23. A pharmaceutical composition comprising a compound as claimed in claim 1 in an amount sufficient to inhibit the activity of dipeptidase, and a pharmaceutically acceptable carrier. 24. A method of inhibiting the activity of dipeptidase in a mammal in need thereof, comprising the step of administering to said mammal a pharmacologically effective amount of the compound as claimed in claim 1.